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Abstract: Over the last decade, increasing evidence has reinforced the key role of metabolic
reprogramming in macrophage activation. In addition to supporting the specific immune response
of different subsets of macrophages, intracellular metabolic pathways also directly control the
specialized effector functions of immune cells. In this context, iron metabolism has been recognized
as an important component of macrophage plasticity. Since macrophages control the availability
of this essential metal, changes in the expression of genes coding for the major proteins of iron
metabolism may result in different iron availability for the macrophage itself and for other cells
in the microenvironment. In this review, we discuss how macrophage iron can also play a role
in immunometabolism.
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1. Introduction
Over the last decade, interest in immunometabolism—the interaction between immunological
and metabolic systems at both the body and cellular levels—has grown considerably. Although the
metabolic pathways of several types of immune cells, such as T cells—which contribute to immune
modulation in cancer through their metabolic connection with tumor cells [1]—have received attention,
most studies have focused on macrophage immunometabolism. In fact, it is increasingly appreciated
that the functions of these cells extend beyond immune defense. Indeed, metabolism is not only a
system to produce energy, but also a source of a variety of intermediates with relevant biological
function in innate immunity and inflammatory response. Under the influence of signals from the
microenvironment, cells of the monocyte–macrophage lineage undergo a complex reprogramming
toward distinct functional phenotypes [2]. Emerging evidence has shown that immunometabolism is an
important factor of the functional phenotype that characterizes the different macrophage populations,
such as those present in sites of infections, tissue injury, tumors, atherosclerotic plaques, adipose
tissue, etc. In this review, we address the cell-intrinsic metabolic functions that contribute to determine
the functional activity of macrophages focusing in particular on iron metabolism, which has been
recognized as one of the selected metabolic features of different classes of macrophages [3].
2. Macrophage Polarization
Macrophages play a variety of distinct roles both in pathological conditions, such as inflammation,
and physiological tissue homeostasis. To fulfil these tasks, macrophage populations are able to
acquire different phenotypes depending on environmental and immune signals, which polarize
macrophages to a range of activation states classified in two major groups: classical pro-inflammatory
(M1) macrophages endowed with cytotoxic and microbicidal functions, which are typically induced
following activation of toll-like receptors (TLR) by pathogen products such as lipopolysaccharide (LPS),
or alternative anti-inflammatory (M2) macrophages, which respond to anti-inflammatory cytokines
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like interleukin 4 (IL-4) and are involved in cell growth and tissue remodelling [4] (Figure 1). In spite of
the oversimplification, this classification faithfully represents the polarization of macrophages in most
pathophysiological settings. The behaviour and the gene expression profile of differently polarized
macrophages show considerable differences, but recent studies have shown that several divergences
in cellular metabolism also contribute significantly to the diversity of the M1 and M2 populations.
Notably, the metabolic changes, which are influenced by signals from the microenvironment, in turn
support the specialized functions of macrophage subsets [5]. In addition, recent studies showed that
altering macrophage metabolism can also reshape their functions [6]. This may offer the possibility to
exploit metabolic pathways to alter the role of macrophages in a variety of pathologic conditions in
which myelomonocytic cells are a key component, such as tumors, obesity, atherosclerosis.
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Macrophage plasticity includes changes in amino acid metabolism (Figure 1); in fact, a 
well-known distinctive feature of M1 macrophages is the inducible conversion of arginine into nitric 
oxide (NO), a reactive compound important for microbial killing. Conversely, arginase-dependent 
metabolism of arginine in M2 cells on the one hand depletes arginine required for NO synthesis in 
macrophages and for T cell immunity [7]; on the other hand leads to the production of ornithine, 
thus possibly contributing to collagen synthesis, consistent with the healing function of M2 [3,5]. 
The metabolism of tryptophan which can be converted in different compounds along two main 
pathways represents another example of the connection between immune function and amino acid 
metabolism. Tryptophan can be metabolized by the heme-containing indoleamine 2,3-dioxygenase 1 
(IDO1) or tryptophan mono-oxygenase: IDO1 catalyzes the initial reaction of the pathway that 
transforms tryptophan into kynurenine, a product that exerts major immunosuppressive effects by 
inhibiting T cell immunity and impairing chemotaxis of neutrophils [7] (Figure 2). IDO1 can be 
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immunity [9]. The immunosuppressive activity of IDO1, which is also considered a marker of M2
polarization, has been ascribed to its ability to deplete the microenvironmental tryptophan pools for
T cells while favoring the accumulation of kynurenine and the production of ligands for the aryl
hydrocarbon receptor with ensuing synthesis of pro-inflammatory cytokines [10]. Consistent with the
inhibitory role of kynurenine, lack of tetrahydrobiopterine (BH4), which is a cofactor for tryptophan
mono-oxygenase, favored tryptophan metabolism by IDO1, thus repressing T cells proliferation and
impairing mitochondrial respiration and energy production [11].
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found in T cells lacking tetrahydrobiopterin (BH4) (see text), it is conceivable that the conversion of
tryptophan by tryptophan mono-oxygenase results in high iron levels and efficient mitochondrial
activity, whereas the kynurenine pathway initiated by IDO1 activity leads to the formation of the iron
chelator picolinic acid.
3.2. Glucose Metabolism
The differences in amino acid metabolism described above are well-known and have long
been used to define macrophages subsets, but recently a growing interest highlighted the role of
glucose metabolism in this context (reviewed in Reference [12–14]) (Figure 1). M1 macrophages
produce ATP mainly through aerobic glycolysis, i.e., the metabolism of glucose to lactate despite
oxygen availability. Reactive oxygen species-mediated hypoxia inducible factor 1 α (HIF1α) induction
results in glycolysis upregulation [15]. This pathway is less efficient in generating ATP than the
mitochondrial respiration, but it allows the cells to generate building blocks needed for the synthesis
of nucleotides, amino acids and lipids. Moreover, the higher levels of glucose 6-phosphate generated
by increased glycolysis can stimulate the pentose phosphate pathway, thus also providing more
of the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), a key cofactor for
a variety of biosynthetic processes, including lipid synthesis. Therefore, M1 macrophages adapt
their energy metabolism to secure enough ATP, while also supporting biosynthetic functions needed
to sustain proliferation and synthesis of cell structures and inflammatory molecules. At the same
time, the other metabolic process observed in M1 macrophages is the inhibition of mitochondrial
oxidative phosphorylation [12]. This is attained by suppressing the tricarboxylic acid (TCA) cycle at
two distinct levels, with concomitant generation of intermediates that are used for protein and lipid
synthesis. The block of isocitrate dehydrogenase (IDH) results in the accumulation of acetyl CoA
and citrate, which is then exported from the mitochondria to the cytosol where it can be converted
by acetyl-CoAcarboxylase (ACC) to malonyl-CoA, which is then used to synthesize fatty acids,
important precursors for the expansion of membranes, such as the endoplasmic reticulum. Suppression
of succinate dehydrogenase (SDH) is obtained through a recently discovered pathway based on
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TLR4-mediated induction of cis-aconitic acid decarboxylase/immune-responsive gene 1 (CAD/Irg1),
an enzyme that drives the conversion of cis-aconitate, the intermediate between citrate and isocitrate
in the TCA cycle, to itaconate, a metabolite possessing both anti-inflammatory and anti-microbial
properties [16] (Figure 3). It has been shown that itaconate, known as industrial polymer since almost
a century [17], inhibits SDH activity, thereby decreasing fumarate production. Since SDH is also a
component of the complex II of the electron transport chain, induction of CAD/Irg1 activity affects two
key steps of cellular oxidative energy production. Moreover, by inhibiting the prolyl hydroxylases
involved in HIF1α degradation pathway, succinate accumulation may concur to the induction of
glycolysis reported above. The latter effect is also achieved by itaconate-mediated repression of fatty
acid biosynthesis from glucose. Interestingly, itaconate is also endowed with antimicrobial properties
against a variety of microorganisms, as it is transported from the mitochondria, where CAD/Irg1
is located, to phagosomes in which it inhibits microbial isocitrate lyase, an enzyme involved in the
glyoxylate pathway required for survival when glucose availability is limited [16]. Itaconate is also
secreted [17], as revealed by its presence in serum, and hence it also traverses the cytoplasm. Therefore,
mitochondrial or cytosolic itaconate might play regulatory roles while phagosomal and extracellular
itaconate participates in anti-microbial action. A recent study [18] reported that the activity of one
isoform (BCAT1) of branched chain aminotransferases, multi-level regulators of the TCA cycle and
oxidative phosphorylation, is required for itaconate production and metabolic reprogramming in
human macrophages, thus showing the interaction of different nutrient metabolism (amino acids and
glucose) in pro-inflammatory macrophage function.Pharmaceuticals 2019, 12, x FOR PEER REVIEW 5 of 10 
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Figure 3. Alternative pathways of cis-aconitate metabolism. Iron availability and reactive molecules
produced under inflammatory condition like nitric oxide (NO) can target the iron-sulfur cluster and
alter aconitase activity, thus affecting the amount of cis-aconitate available for the decarboxylating
activity of CAD/Irg1 and the production of itaconate.
Notably, the link between macrophage metabolism and functionality is underlined by the
evidence that metabolic pathways of M1 macrophages contribute specifically to their pro-inflammatory
role. Moreover, metabolites can also be employed as immunoregulators in order to control the
extent and duration of the inflammatory response. For example, the lactate produced by activated M1
macrophages through glycolysis accumulate and exerts an immunosuppressive function by stimulating
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M2 polarization of macrophages. Interestingly, lactate appears to be one of the factors produced by
tumor cells that promote the formation of M2-like tumor associated macrophages (TAM) [19].
On the other hand, M2 cells show high levels of oxidative phosphorylation and mitochondrial
activity. The TCA cycle is fueled by consumption of fatty acids undergoing beta oxidation and also by
glutamine utilization to form α-ketoglutarate. To support these reactions, mitochondrial biogenesis
is also induced. Interestingly, the key metabolic regulator mechanistic target of rapamycin (mTOR)
is involved also in macrophage metabolism and activation. In fact, inducers of M2 polarization
like IL-4 signal through the mTOR pathway to promote fatty acid oxidation (FAO) and glucose
consumption for oxidative phosphorylation, two metabolic changes that are critical for macrophage
alternative activation [20]. A recent study has demonstrated that upregulating FAO in macrophages
of hypercholesterolemic mice via miR-33 inhibition drives macrophages toward an M2 state and
reduces atherosclerosis [21]. This study emphasizes how metabolic reprogramming of macrophages
can influence disease outcome.
The anti-inflammatory and pro-resolving function of M2 macrophages is involved also in
efferocytosis, the process by which apoptotic cells are cleared by phagocytes, primarily resident
macrophages. Recent findings have shown that two distinct metabolic pathways are required to prevent
unwanted inflammation and promote repair by creating an anti-inflammatory tissue environment.
One study showed the importance of glycolysis and lactate release [22], whereas Zhang et al. [23]
described how FAO starts a mechanism leading to the production of anti-inflammatory IL-10. These
results indicate that macrophages adopt separate but converging mechanisms to alter their metabolism
and thus drive an anti-inflammatory response.
Amino acid and glucose metabolism are linked in reprogramming macrophage function. In fact,
recent findings have shown that NO also impacts on mitochondrial cell bioenergetic pathways, probably
thanks to its reactivity against iron-containing Fe-S clusters and heme moieties that are present in
several proteins of the electron transport chain and TCA cycle. In fact, knock down of iNOS restored
mitochondrial ATP production through oxidative metabolism in M1 macrophages. These forces
activated macrophages to bring in glucose and use glycolytic metabolism to produce energy [12].
Notably, both the accumulation of citrate described above and the generation of glucose 6-phosphate
by glycolysis, with consequent stimulation of the pentose phosphate pathway, favor NO production,
thereby inducing a feedforward loop of inflammatory activation.
Despite our increased understanding of macrophage immunometabolism as an important
determinant of the pathophysiological conditions in which macrophages are involved, it should
be kept in mind that several issues remain to be explored and clarified. Some of the major challenges
and concerns are reported below. In the same way as the distinction of M1 and M2 macrophages
between pro- and anti-inflammatory, respectively, is an oversimplification, also describing their
metabolism as glycolytic or depending on oxidative phosphorylation does not reflect the variety of
phenotypes and metabolic profiles that can be obtained by in vitro exposure to different stimuli or,
even more, to the distinct macrophage subsets occurring in vivo. An example of the diverse effects
on metabolism of different M1 polarizing stimuli is represented by the response of mitochondrial
metabolism to LPS, which is downregulated in bone marrow-derived macrophages and upregulated
in peritoneal macrophages, despite a similarly strong inflammatory response [24]. Another striking
example is provided by TAM, which are usually considered M2-like but show a glycolytic metabolism
similar to that of in vitro polarized M1 cells (discussed in Reference [14]). Moreover, IRG1-itaconic
acid production, which is typical of M1 cells, has been shown to be linked to the modulation of M2-like
macrophage polarization in the revascularization of ischaemic muscle [25]. It should be also kept in
mind that most studies investigating immunometabolism were performed in mouse models and in
several instances the maintenance of the observed effects in humans remains to be investigated and
demonstrated. Indeed, several differences exist between mouse and human macrophages, such as
the inability of human macrophages to produce significant amounts of a key regulator of metabolic
reprogramming like NO.
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4. Macrophages and Iron Metabolism
Iron is a redox-active metal required for the activity of essential enzymes involved in a variety
of cellular functions, but excess iron is potentially toxic as a catalyst of oxidative stress. Therefore,
the appropriate iron concentration in the cells and organisms is homeostatically maintained by several
mechanisms. The role of macrophages in iron metabolism has been covered extensively in this
Special Issue [26]. At the systemic level, macrophages are key regulators of iron trafficking [27,28].
Spi-C-dependent splenic reticuloendothelial cells clear senescent erythrocytes and release iron back
to circulation, thus providing iron needed for erythroid precursors proliferation and hemoglobin
synthesis [29]. On the other hand, iron sequestration by pro-inflammatory macrophages represents a
recognized and efficient bacteriostatic response [30,31]. Moreover, iron is required for hemoproteins
essential for macrophage activity in inflammation, such as NADPH oxidase 2, cyclooxygenases 1 and
2, inducible nitric oxide synthase, etc. [29]. Consistent with their different functions in homeostatic and
inflammatory conditions, polarized macrophages also show a distinct expression of genes involved
in iron homeostasis [28,32], in which M1 cells withhold iron whereas M2 are prone to iron release to
tissues (Figure 1). High expression of the iron storage protein ferritin correlates with iron retention
by in vitro polarized M1 macrophages. On the other hand, alternatively activated M2 macrophages
show an elevated capacity for CD163-dependent uptake and heme oxygenase-mediated catabolism of
heme-associated iron, as well as high expression of ferroportin (FPN), the only known mammalian
iron exporter [33]. This FPN-mediated sustained iron release may significantly contribute to the role
of M2 macrophages in various pathophysiological conditions, such as tissue repair, and also tumor
growth [28], as TAM acquire a M2-like phenotype [34]. However, the effect of iron on TAM polarization
remains to be fully understood. In fact, it has been shown that high doses of iron can shift TAM,
which usually have a pro-tumor activity, to the anti-tumor M1 phenotype [35]. Conversely, it has
been described that an intracellular iron-chelator can switch TAM from their iron-release phenotype
toward iron storage [36]. In this context, it is interesting that TAM macrophages can also be a source of
extracellular ferritin in the tumor microenvironment and ferritin was able to stimulate the growth of
cancer cells in an iron-independent way, at least in vitro [37].
Moreover, we recently demonstrated that macrophage FPN-dependent supply of iron to the
microenvironment is necessary for stromal and parenchymal cells multiplication, differentiation and
activity, both in the physiological context of hair follicle growth and in the pathophysiological setting
of wound healing, two conditions sharing many similarities including fast cell replication [38]. In fact,
loss of macrophage FPN causes hair follicle alterations and alopecia by inhibiting the proliferation
of neighbouring hair follicle cells. Similarly, iron retention in macrophages delayed wound healing
in mice lacking FPN in macrophages by affecting stromal cells proliferation, blood and lymphatic
vessels formation and fibrogenesis. These findings indicated that iron should be included in the
list of trophic mediators produced by macrophages that are required for tissue homeostasis and
repair. Although in these settings iron retention in macrophages had no impact on the inflammatory
processes accompanying wound healing [38], other studies suggested that under conditions of massive
iron deposition caused by hemolysis iron accumulation in macrophages can activate them to a
pro-inflammatory M1 phenotype [39–41]. The conflicting results may be related to the amount of iron
stored as well as to the exposure to different iron sources, as heme iron is highly toxic [42].
5. Macrophage Iron and Immunometabolism
The differences in iron metabolism existing in the various macrophage subsets can be relevant
also for immunometabolism. As reported above, in pro-inflammatory macrophages CAD/Irg1
decarboxylates cis-aconitate to generate itaconate, a compound with antimicrobial functions [16,17].
Cis-aconitate, an intermediate in the conversion of citrate to isocitrate, is the substrate of both
mitochondrial and cytosolic aconitases. The latter represents an alternative form of iron-regulatory
protein 1 (IRP1), an RNA-binding protein which controls the synthesis of proteins involved in
intracellular iron usage, storage or transport [43]. The availability of iron to assemble the iron-sulfur
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cluster dictates the switch between the enzymatically active holoprotein endowed with aconitase
activity and the RNA-binding apoform which controls iron homeostasis [44] (Figure 3). We have
shown that in macrophages NO is able to induce concomitant inactivation of cytosolic aconitase
and activation of IRP1, attributable to disassembly of the Fe-S cluster [45]. This switch should
result in cis-aconitate accumulation and increased availability of this substrate to CAD/Irg1-mediated
conversion to itaconate. Therefore, this process could represent a still unexplored pathway used by
NO-producing inflammatory macrophages to favor the generation of an antimicrobial compound.
In addition, by targeting iron-sulfur clusters the generation of NO can also affect macrophage metabolic
activities [46]. In fact, in Toll-like receptor-activated mouse macrophages, NO-mediated damage
to iron-sulfur proteins compromises mitochondrial oxidative metabolism and thus constitutes an
additional mechanism contributing to the shift toward the glycolytic pathway that characterizes M1
cells. Notably, genes involved in iron-sulfur cluster biogenesis, such as ISCU and NSF1, were found to
be preferentially expressed in M2 polarized human macrophages [32], which rely on mitochondrial
oxidative phosphorylation for energy production. In the same context, by influencing the formation of
the iron-sulfur cluster of mitochondrial aconitase, iron availability in the mitochondria could determine
whether cis-aconitate is decarboxylated by CAD/Irg1 or converted to isocitrate by aconitase (Figure 3).
Iron may be involved also in amino acid catabolism. Tryptophan mono-oxygenase-mediated
tryptophan metabolism contributes to maintain high iron levels and efficient mitochondrial
respiration [11], whereas tryptophan degradation by IDO1 through the kynurenine pathway leads
to formation of picolinic acid, which is an iron chelator [47] (Figure 2). By depleting the cells of
iron, which is essential for enzymes involved in DNA synthesis like ribonucleotide reductase [48],
iron sequestration by picolinic acid may contribute to the immunosuppressive activity of the kynurenine
pathway, which impairs T cells proliferation and activity [49]. Moreover, the ability of picolinic acid to
amplify IFN-γ-mediated NO production in macrophages, an event connecting arginine and tryptophan
metabolism [50], may depend on the induction of nitric oxide synthase (NOS) mRNA expression by the
hypoxia inducible transcription factor (HIF), which is also induced by iron deficiency [51]. Therefore,
iron may contribute to the immunosuppressive activity that renders IDO1 an interesting target of
pharmacological inhibitors for cancer therapy [52].
A link between metabolic, inflammatory, and iron-regulatory pathways has been provided by
evidence showing that mTOR regulates iron homeostasis by decreasing transferrin receptor (TfR1)
stability and hence iron uptake. mTOR activates tristetraprolin (TTP), a protein involved in suppression
of immune responses, which binds to TfR1 mRNA and enhances its degradation [53]. At the same time,
TTP, which is induced by iron deficiency, promotes downregulation of iron-requiring genes, in particular
those coding for mitochondrial proteins involved in energy production, thus facilitating survival
when iron is scarce. Although these results were found in fibroblasts and myoblasts, it is tempting
to speculate that a similar process can occur in macrophages, consistent with the demonstration that
metabolic reprogramming mediated by the mTOR pathway is required for macrophage alternative
activation [20].
Another example of the interaction between iron and immunometabolism was provided by
the comparison of differences in gene expression profiles between mouse non-activated bone
marrow-derived macrophages and non-activated peritoneal macrophages, which highlighted a
differential expression of genes involved in heme biosynthesis [24], thus confirming a previous
observation in human in vitro polarized macrophages [32].
6. Concluding Remarks
Recent advances in the availability of molecular and biochemical methods have highlighted that
intracellular metabolic pathways control the effector functions of macrophages, as exemplified by the
distinct metabolic signature of differently polarized macrophages, which show significant differences
in pathways of energy production, amino acid metabolism and iron homeostasis. These processes are
intertwined and we have tried to draw attention to the role of iron in these settings.
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In particular, the effect of variations in iron availability on immunometabolism may impinge
on the relevant role played by macrophages in several pathologic conditions like obesity, diabetes,
cardiovascular diseases, tumors. Indeed, iron homeostasis is altered in adipose tissue associated
macrophages, which have a pathogenetic role in obesity favoring insulin resistance [54], and macrophage
iron is key in the development and progression of atherosclerotic plaques (discussed in Reference [55]).
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